These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31502413)

  • 1. Disseminated anaplastic pleomorphic xanthoastrocytoma with posttreatment fat necrosis during combined BRAF and MEK inhibitors therapy.
    Phadnis SS; Chen L; Wang WL; Migden MR; Zaky W
    Pediatr Blood Cancer; 2019 Dec; 66(12):e27974. PubMed ID: 31502413
    [No Abstract]   [Full Text] [Related]  

  • 2. Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab.
    Thomas AA; Tucker SM; Nelson CJ; Nickerson JP; Durham SR; Homans AC
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27465. PubMed ID: 30255633
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.
    Hussain F; Horbinski CM; Chmura SJ; Yamini B; Lukas RV
    Neurologist; 2018 Sep; 23(5):163-166. PubMed ID: 30169370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
    Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
    J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma.
    Migliorini D; Aguiar D; Vargas MI; Lobrinus A; Dietrich PY
    Neurology; 2017 Mar; 88(13):1291-1293. PubMed ID: 28235815
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
    Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
    J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.
    Balasubramanian A; Gunjur A; Gan HK; Perchyonok Y; Cher LM
    J Clin Neurosci; 2020 Sep; 79():269-271. PubMed ID: 33070910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
    Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
    J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.
    Sun Y; Alberta JA; Pilarz C; Calligaris D; Chadwick EJ; Ramkissoon SH; Ramkissoon LA; Garcia VM; Mazzola E; Goumnerova L; Kane M; Yao Z; Kieran MW; Ligon KL; Hahn WC; Garraway LA; Rosen N; Gray NS; Agar NY; Buhrlage SJ; Segal RA; Stiles CD
    Neuro Oncol; 2017 Jun; 19(6):774-785. PubMed ID: 28082416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment.
    Atahan C; Arslantas E; Ersen Danyeli A; Celik L; Bozkurt G; Ugurluer G; Corapcioglu FV; Ozyar E
    J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1005-e1009. PubMed ID: 37700448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
    Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
    J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
    [No Abstract]   [Full Text] [Related]  

  • 13. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
    Brown NF; Carter T; Mulholland P
    CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.
    Amayiri N; Swaidan M; Al-Hussaini M; Halalsheh H; Al-Nassan A; Musharbash A; Tabori U; Hawkins C; Bouffet E
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):478-482. PubMed ID: 29200156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
    Drago JZ; Lawrence D; Livingstone E; Zimmer L; Chen T; Giobbie-Hurder A; Amann VC; Mangana J; Siano M; Zippelius A; Dummer R; Goldinger SM; Sullivan RJ
    Melanoma Res; 2019 Feb; 29(1):65-69. PubMed ID: 30376465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.
    Lukas RV; Merrell RT
    CNS Oncol; 2018 Apr; 7(2):CNS10. PubMed ID: 29708404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.
    Niemantsverdriet M; Schuuring E; Elst AT; van der Wekken AJ; van Kempen LC; van den Berg A; Groen HJM
    J Thorac Oncol; 2018 Dec; 13(12):e249-e251. PubMed ID: 30467046
    [No Abstract]   [Full Text] [Related]  

  • 18. Concurrent BRAF/MEK Inhibitors in
    Schreck KC; Guajardo A; Lin DDM; Eberhart CG; Grossman SA
    J Natl Compr Canc Netw; 2018 Apr; 16(4):343-347. PubMed ID: 29632053
    [No Abstract]   [Full Text] [Related]  

  • 19. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
    Purkait S; Bansal S; Malgulwar PB
    Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
    Grän F; Goebeler M; Gesierich A
    Eur J Dermatol; 2019 Feb; 29(1):107-108. PubMed ID: 30998207
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.